Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Albany Molecular Research Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 EPS Guidance; Issues Q2 2013 Guidance

Tuesday, 7 May 2013 08:00am EDT 

Albany Molecular Research Inc announced that for fiscal 2013, it maintains its revenue outlook of $205-$213 million, and increasing adjusted EPS range to between $0.52 to $0.65 from the previously communicated $0.34 to $0.52. For the second quarter of 2013, it expects contract revenue between $48 and $50 million and adjusted EPS of between $0.09 and $0.12. 

Company Quote

0.02 +0.12%
17 Apr 2014